Schering PEG-Intron/Rebetol Wait List Patients To Receive Drug By April
Executive Summary
Schering-Plough expects patients being put on a waiting list for PEG-Intron this month to be able to receive the drug by April, the company said
You may also be interested in...
Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron?
Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26
Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron?
Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26
Roche Pegasys Has $291 WAC; Launch Includes 12 Weeks Of Free Samples
Roche's Pegasys has a wholesale acquisition cost of $291 for one week of the hepatitis C therapy